Wins Finance Hldgs (OTC:WINSF) Stock, Quote.Headers.trade-ideas

Wins Finance Holdings Inc is a diversified investment and asset management company. It is in the business of leasing, financial advisory, financial guarantees, and partnerships. The Company operates and manages its business in three reportable segments, namely, the provision of financial services, medical consulting services and Sales medical equipment in the PRC domestic market.

WINS FINANCE HOLDINGS INC by Wins Finance Holdings Inc.

Wins Finance Holdings Inc

News

MTAL

Metals Acquisition Plans To Seek Shareholder Approval To Change Company Name To 'MAC Copper Limited'

Needham analyst John Todaro maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and raises the price target from $15 to $16.5.

Price Target

Analyst Ratings

Needham Maintains Buy on Hut 8, Raises Price Target to $16.5

Baird analyst Joe Vruwink initiates coverage on ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Outperform rating and announces Price Target of $280.

Initiation

Baird Initiates Coverage On ResMed with Outperform Rating, Announces Price Target of $280

HC Wainwright &amp; Co. analyst Scott Buck reiterates Mogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) with a Buy and maintains $6 price target.

Reiteration

MOGO

HC Wainwright & Co. Reiterates Buy on Mogo, Maintains $6 Price Target

Baird analyst Joe Vruwink initiates coverage on TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) with a Outperform rating and announces Price Target of $200.

TMDX

Baird Initiates Coverage On TransMedics Gr with Outperform Rating, Announces Price Target of $200

Baird analyst Joe Vruwink initiates coverage on Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Outperform rating and announces Price Target of $73.

PCOR

Baird Initiates Coverage On Procore Technologies with Outperform Rating, Announces Price Target of $73

Redburn Atlantic analyst Peter Low downgrades Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) from Buy to Neutral and raises the price target from $119 to $120.

Downgrades

Redburn Atlantic Downgrades Exxon Mobil to Neutral, Raises Price Target to $120

Redburn Atlantic analyst Peter Low downgrades BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) from Buy to Neutral.

Redburn Atlantic Downgrades BP to Neutral

RBC Capital analyst Nik Modi downgrades Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) from Outperform to Sector Perform and announces $24 price target.

KVUE

RBC Capital Downgrades Kenvue to Sector Perform, Announces $24 Price Target

Zuora customers can instantly activate its&nbsp;AI paywall&nbsp;in minutes for a deeper understanding of subscriber behavior to drive conversion and revenue growth.

Zuora Reveals New AI Enhancements At Subscribed Live London

Under the terms of the collaboration agreement, Generate will receive a total upfront payment of&nbsp;$65 million&nbsp;in cash from Novartis, which includes&nbsp;$15 million&nbsp;for the purchase of equity in Generate. Generate is also eligible to receive more than&nbsp;$1 billion&nbsp;in performance-based milestone payments, in addition to tiered royalties up to low double-digits. The number of targets and therapeutic areas are not being disclosed.

Contracts

Generate:Biomedicines Enters Multi-target Collaboration With Novartis To Discover, Develop Protein Therapeutics Across Multiple Disease Areas; Potential Total Transaction Valued At More Than $1B

IMMP

Immutep Received €2.19M R&D Tax Incentive Payment From French Government Under CIR Scheme

Macquarie analyst Ellie Jiang initiates coverage on DiDi Global (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DIDIY#OTC">DIDIY</a>) with a Outperform rating and announces Price Target of $5.5.

DIDI GLOBAL INC S/ADR by DiDi Global Inc.

DIDIY

Macquarie Initiates Coverage On DiDi Global with Outperform Rating, Announces Price Target of $5.5

BCLI

BrainStorm Cell Therapeutics Plans To Share Latest Update On NurOwn At This Year's NEALS Meeting

Catalyst Pharmaceuticals, Inc.&nbsp;("Catalyst" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") to commercialize FIRDAPSE&#xAE; (amifampridine) Tablets 10 mg for treatment of patients with Lambert-Eaton Myasthenic Syndrome ("LEMS") in Japan. This approval marks a pivotal advancement in the treatment of LEMS, a rare autoimmune disorder that can severely impact quality of life and represents a significant step forward in addressing the unmet needs of patients affected by LEMS in Japan.
"We are pleased that our partner, DyDo, has secured regulatory approval for FIRDAPSE in Japan. This represents a meaningful milestone, bringing renewed hope to patients and further affirming FIRDAPSE's proven effectiveness in the treatment of LEMS," said Richard J. Daly, Catalyst's President and Chief Executive Officer. "This achievement underscores our unwavering commitment to advancing patient care. We appreciate the collaborative efforts of our partner in securing this approval, and we remain focused on expanding our innovative rare disease product portfolio beyond the U.S. to make a meaningful impact on patients' lives worldwide."
FIRDAPSE (amifampridine) is a leading therapy indicated in the United States for the treatment of LEMS in adults and pediatric patients six years of age and older. LEMS is a rare autoimmune disorder characterized by muscle weakness and fatigue. About 50% of people with LEMS have underlying cancer, as LEMS is observed in approximately 3% of small-cell lung cancer patients. FIRDAPSE is the only U.S. FDA-approved, evidence-based treatment for LEMS. As a cornerstone of Catalyst's commitment to serving those with rare diseases, FIRDAPSE is supported in the U.S. by a comprehensive patient support program to help ensure accessibility and assistance for eligible U.S. patients.

Government

Regulations

CPRX

Catalyst Pharma's FIRDAPSE Approved in Japan for Rare Autoimmune Disorder Lambert-Eaton Myasthenic Syndrome ("LEMS")

Buybacks

ARLO

Arlo Technologies Plans Repurchase Of Up To An Aggregate Of $50M Of Shares Of Its Common Stock

The application to the PMDA was based on the efficacy and safety data from TRAILBLAZER-ALZ 2 Phase 3 clinical study.

Eli Lilly Says Japan Has Approved Kisunla (Donanemab-azbt, 350 Mg/20 mL Every Four Weeks Injection For IV Infusion) For Early Symptomatic Alzheimer's Disease

Revelation Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revbiosciences.com%2Fnews73&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=topline+data+from+the+Phase+1+clinical+study+of+Gemini&amp;index=1&amp;md5=251ba51b272b745c89d17af8755c3483">topline data from the Phase 1 clinical study of Gemini</a> released on June 24, 2024.
Using high sensitivity serum IL-10 biomarker analysis to gain further insight into Gemini's capability for resolution of inflammation, Revelation tested samples from the Phase 1 clinical study. It was found that Gemini induced statistically significant, dose dependent changes in circulatory IL-10 at 2 hours post-dose, with a p-value of &lt; 0.05 or greater, at each of the low, mid, and high dose levels, as shown in Figure 1. The change in IL-10 observed for treatment groups relative to placebo, were a 27-fold increase, 162-fold increase, and 309-fold increase for the low, mid, and high dose groups, respectively.
IL-10 is a potent anti-inflammatory protein that downregulates pro-inflammatory cytokines and is an active contributor to initiating reduction of inflammation. The significant increase of anti-inflammatory IL-10 with no significant increase in pro-inflammatory IL-1β and TNF-α confirms TLR4 binding unique to Gemini, and is further evidence of the reprogramming of the innate immune response, enabling Gemini to initiate resolution of inflammation and promote the healing process.
The observed increase of IL-10 in humans is consistent with prior preclinical studies performed by Revelation where an increase in IL-10 was observed in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revbiosciences.com%2Fnews60&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=healthy+animals&amp;index=2&amp;md5=dba735604f9f7922b050fc373a1fd8dd">healthy animals</a> as well as efficacy models, including the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fstatic1.squarespace.com%2Fstatic%2F5f536d50b94bfb444769fc95%2Ft%2F65f114641526fa578482eaac%2F1710298213540%2FPrevention%2Bof%2BAKI%2Bw%2BGemini%2BCRRT%2BPresentation%2Band%2BPoster%2B2024.pdf&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=ischemia%2Freperfusion+model+of+acute+kidney+injury&amp;index=3&amp;md5=9a89ab3850d72e11e309d58197a508fc">ischemia/reperfusion model of acute kidney injury</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revbiosciences.com%2Fnews48&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=unilateral+ureteral+obstruction+model+of+kidney+injury&amp;index=4&amp;md5=c3be07701ccf2cae5a96619526bd4589">unilateral ureteral obstruction model of kidney injury</a>. This demonstrates the potential for Gemini in our target indications, including prevention of AKI following cardiac surgery.

REVB

Revelation Biosciences Observes IL-10 Increase in Phase 1 Gemini Trial

Keybanc analyst Jason Celino initiates coverage on Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) with a Overweight rating and announces Price Target of $70.

Keybanc Initiates Coverage On Dayforce with Overweight Rating, Announces Price Target of $70

KBR was awarded this contract under the Department of Defense Information Analysis Center&#39;s (DoDIAC) multiple-award contract (MAC) vehicle. These IAC MAC task orders (TOs) are awarded by the U.S. Air Force&#39;s 774th Enterprise Sourcing Squadron to develop and create new knowledge for the enhancement of the DTIC repository and the R&amp;D and S&amp;T community.

KBR Bags Estimated $113M Task Order To Perform Aeronautical Systems Research, Development, Test And Evaluation For AFLCMC/WL At Wright-Patterson Air Force Base, Ohio Over 5 Years

Wins Finance Holdings, Inc. (WINSF) has released an update. Wins Finance Holdings Inc. announced the issuance of options for 3.6 million ordinary s...

Wins Finance Awards Share Options to Top Brass

Wins Finance Holdings, Inc. (WINSF) has released an update. Wins Finance Holdings Inc. has entered into a Share Subscription Agreement with Jude Go...

Wins Finance Announces Major Stock Subscription

Wins Finance Holdings (WINSF) has released an update. Wins Finance Holdings Inc. has reported a shift in its strategic focus towards the medical eq...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Wins Finance Hldgs

Wins Finance Hldgs (WINSF) Forecast

Wins Finance Hldgs (OTC:WINSF) Stock, Quote.Headers.trade-ideas